Penumbra, Inc. $PEN Stake Raised by One Capital Management LLC

One Capital Management LLC boosted its holdings in Penumbra, Inc. (NYSE:PEN) by 87.4% during the 4th quarter, Holdings Channel.com reports. The fund owned 11,629 shares of the company’s stock after purchasing an additional 5,425 shares during the quarter. One Capital Management LLC’s holdings in Penumbra were worth $3,616,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the business. Norges Bank bought a new stake in Penumbra in the fourth quarter worth about $33,041,000. Eurizon Capital SGR S.p.A. bought a new stake in Penumbra in the fourth quarter worth about $165,000. Future Fund LLC raised its position in Penumbra by 177.6% in the fourth quarter. Future Fund LLC now owns 17,221 shares of the company’s stock worth $5,354,000 after acquiring an additional 11,017 shares in the last quarter. SBI Okasan Asset Management Co.Ltd. bought a new stake in Penumbra in the fourth quarter worth about $2,091,000. Finally, Geode Capital Management LLC raised its position in Penumbra by 2.5% in the fourth quarter. Geode Capital Management LLC now owns 766,510 shares of the company’s stock worth $238,365,000 after acquiring an additional 18,738 shares in the last quarter. 88.88% of the stock is currently owned by institutional investors.

Penumbra Trading Down 0.1%

NYSE:PEN opened at $318.66 on Wednesday. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.02 and a quick ratio of 3.95. Penumbra, Inc. has a fifty-two week low of $221.26 and a fifty-two week high of $362.41. The stock’s 50-day moving average is $328.12 and its two-hundred day moving average is $325.22. The stock has a market cap of $12.53 billion, a PE ratio of 73.42, a price-to-earnings-growth ratio of 1.95 and a beta of 0.71.

Penumbra (NYSE:PEN) last released its earnings results on Wednesday, May 6th. The company reported $0.82 earnings per share for the quarter, missing the consensus estimate of $1.06 by ($0.24). Penumbra had a net margin of 11.76% and a return on equity of 10.87%. The business had revenue of $374.76 million for the quarter, compared to analysts’ expectations of $370.47 million. During the same period last year, the firm earned $0.83 EPS. The company’s revenue was up 15.6% compared to the same quarter last year. As a group, equities research analysts forecast that Penumbra, Inc. will post 5.08 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Penumbra news, Director Harpreet Grewal sold 100 shares of Penumbra stock in a transaction dated Thursday, April 2nd. The stock was sold at an average price of $328.22, for a total transaction of $32,822.00. Following the transaction, the director owned 8,719 shares of the company’s stock, valued at $2,861,750.18. The trade was a 1.13% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 2.90% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

PEN has been the topic of several research reports. UBS Group reiterated a “neutral” rating and issued a $374.00 price target on shares of Penumbra in a research report on Thursday, February 26th. Evercore reiterated an “outperform” rating and issued a $335.00 price target on shares of Penumbra in a research report on Thursday, May 7th. Citigroup dropped their price target on shares of Penumbra from $374.00 to $350.00 and set a “neutral” rating on the stock in a research report on Thursday, May 7th. Finally, Wall Street Zen upgraded shares of Penumbra to a “hold” rating in a research report on Saturday, May 9th. Three equities research analysts have rated the stock with a Buy rating and fourteen have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $361.33.

Penumbra Company Profile

Penumbra, Inc is a global healthcare company specializing in the development and manufacture of innovative medical devices that address neurovascular and peripheral vascular conditions. The company focuses on products designed to improve patient outcomes in acute ischemic stroke, aneurysm treatment and peripheral thrombectomy. Penumbra’s technologies are used by interventional neuroradiologists, neurosurgeons and interventional cardiologists in hospitals and clinics around the world.

At the core of Penumbra’s portfolio is its mechanical thrombectomy platform, which includes aspiration catheters and accessory devices engineered to remove blood clots in acute stroke cases.